Antibody discovery and cell line development are becoming more complex—and more competitive. Researchers need tools that can deliver both high-throughput screening and functional insight at the single-cell level.

This newly published article explores how Cyto-Mine^® Chroma, the latest evolution of Sphere Bio’s microfluidic platform, enables precise, real-time sorting and dispensing of cells based on multiple criteria, all within picodroplets.

With four lasers and four independent detection channels, Cyto-Mine^® Chroma supports advanced multiplexed assays for productivity, antigen binding, and viability—all in one run.

• Detection of rare antibody-secreting cells
• Antigen-specific binding assays
• Viability screening and exclusion of apoptotic cells

These capabilities streamline discovery workflows, reduce manual effort, and improve confidence in early-stage decisions—all without compromising cell health.

These findings underscore the powerful multiplexing abilities of Cyto-Mine^® Chroma, establishing it as a vital tool for isolating specific cell populations in both CLD and AbD workflows. — Louis Castel

• The platform reliably detects both localized (antibody-antigen binding) and dispersed (IgG secretion, FRET signal) fluorescence.
• When combined with fluorescently stained cells, it accurately distinguishes between different cell types based on specific staining.
• The platform demonstrated strong sorting accuracy and effective enrichment of target populations following sequential gating.
• Cyto-Mine^® Chroma is a dependable solution for multiplexing assays in both CLD (productivity and viability) and AbD (productivity and antigen specificity).

Learn how Cyto-Mine^® Chroma is transforming functional single-cell analysis in antibody discovery and cell line development.

This is part of our Editorial Coverage series, highlighting Sphere Bio’s contributions to leading scientific and industry publications. Stay updated on how our technology is shaping the future of biopharmaceutical discovery.